BCYC
Price
$3.21Alerts
Change
+$0.02 (+0.63%)
Updated
Nov 17, 04:59 PM (EDT)
Capitalization
252.67M
105 days until earnings call
Intraday BUY SELL Signals
DNLI
Price
$18.00Alerts
Change
-$0.08 (-0.44%)
Updated
Nov 17, 04:59 PM (EDT)
Capitalization
3.21B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs DNLI

BCYC vs DNLI Comparison Chart in %
View a ticker or compare two or three
VS
BCYC vs. DNLI commentary
Nov 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and DNLI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BCYC with price predictions
Nov 16, 2026

Aroon Indicator for BCYC shows an upward move is likely

BCYC's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 137 similar instances where the Aroon Indicator showed a similar pattern. In 122 of the 137 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +8.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in 185 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

BCYC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCYC as a result. In 77 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for BCYC turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

BCYC moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.495) is normal, around the industry mean (3.586). P/E Ratio (-1.322) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for DNLI with price predictions
Nov 16, 2026

DNLI's RSI Indicator recovers from oversold territory

The RSI Oscillator for DNLI moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 23 of the 26 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +3.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 206 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNLI as a result. In 74 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for DNLI turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 45 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

DNLI moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for DNLI moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

DNLI broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for DNLI entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.841) is normal, around the industry mean (3.586). P/E Ratio (-7.067) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (2.300) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BCYC vs DNLI: Fundamental Ratings
BCYC
DNLI
OUTLOOK RATING
1..100
1026
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
7357
P/E GROWTH RATING
1..100
2929
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (36) in the null industry is somewhat better than the same rating for DNLI (82) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than DNLI’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to DNLI’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as DNLI (98) in the Biotechnology industry. This means that BCYC’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (57) in the Biotechnology industry is in the same range as BCYC (73) in the null industry. This means that DNLI’s stock grew similarly to BCYC’s over the last 12 months.

DNLI's P/E Growth Rating (29) in the Biotechnology industry is in the same range as BCYC (29) in the null industry. This means that DNLI’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCDNLI
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
76%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
80%
COMPARISON
Comparison
Nov 17, 2026
Stock price -- (BCYC: $3.18 vs. DNLI: $18.08)
Brand notoriety: BCYC and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 161% vs. DNLI: 70%
Market capitalization -- BCYC: $252.67M vs. DNLI: $3.21B
BCYC [@Biotechnology] is valued at $252.67M. DNLI’s [@Biotechnology] market capitalization is $3.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green while DNLI’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 1 green, 4 red.
According to our system of comparison, BCYC is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 3 bullish TA indicator(s).

  • BCYC’s TA Score: 4 bullish, 4 bearish.
  • DNLI’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than DNLI.

Price Growth

BCYC (@Biotechnology) experienced а -15.65% price change this week, while DNLI (@Biotechnology) price change was -11.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.73%. For the same industry, the average monthly price growth was -7.91%, and the average quarterly price growth was -21.89%.

Reported Earning Dates

BCYC is expected to report earnings on Mar 02, 2027.

DNLI is expected to report earnings on Mar 01, 2027.

Industries' Descriptions

@Biotechnology (-9.73% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with PCVX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then PCVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-5.64%
PCVX - BCYC
59%
Loosely correlated
-2.78%
EDIT - BCYC
55%
Loosely correlated
-13.82%
DYN - BCYC
55%
Loosely correlated
-2.68%
RXRX - BCYC
54%
Loosely correlated
-8.79%
RCKT - BCYC
53%
Loosely correlated
-6.09%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with SRPT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-3.52%
SRPT - DNLI
51%
Loosely correlated
-5.85%
EDIT - DNLI
51%
Loosely correlated
-13.82%
VIR - DNLI
50%
Loosely correlated
-3.82%
VCYT - DNLI
50%
Loosely correlated
-1.32%
BCYC - DNLI
49%
Loosely correlated
-5.64%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RWM14.690.23
+1.59%
ProShares Short Russell2000 (RWM)
ARCM100.02N/A
N/A
Arrow Reserve Capital Management ETF (ARCM)
FDHY47.40-0.12
-0.25%
Fidelity Enhanced High Yield ETF (FDHY)
FMDE41.37-0.54
-1.29%
Fidelity Enhanced Mid Cap Core ETF (FMDE)
TARK33.36-3.34
-9.09%
AXS 2X Innovation ETF (TARK)